Lupin rises on plan to launch around 25 products in US in FY17

16 Aug 2016 Evaluate

Lupin is currently trading at Rs. 1593.30, up by 14.45 points or 0.92% from its previous closing of Rs. 1578.85 on the BSE.

The scrip opened at Rs. 1581.15 and has touched a high and low of Rs. 1597.00 and Rs. 1581.15 respectively. So far 8,316 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1729.50 and Rs. 1540.10 respectively. The current market cap of the company is Rs. 71,823.00 crore.

The promoters holding in the company stood at 46.76%, while Institutions and Non-Institutions held 42.40% and 10.83% respectively.

Drug major Lupin is planning to launch around 25 products in the US market in FY17. Apart from the Gavis portfolio, Fortamet and Glumetza, the company is expecting to launch products like Minastrin and Epzicom. The Mumbai-based firm is planning to go ahead with launches on the dermatology front this year.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.



Lupin Share Price

2103.30 -8.70 (-0.41%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×